Hormone Therapy Guidelines

Introduction to Hormone Therapy

The American College of Physicians recommends using the lowest effective dose for the shortest possible time to minimize risks associated with hormone therapy, and to balance benefits for menopausal symptoms against potential risks 1

For women with hormone-sensitive cancers, careful risk-benefit discussions are needed before considering estrogen therapy, as noted by the Journal of Clinical Oncology 2
Patients with comorbid conditions such as migraine, epilepsy, irritable bowel syndrome, and some psychiatric symptoms may experience improved management of these conditions with estradiol, as recommended by the American Academy of Pediatrics 3
Women with a history of perimenopausal depression may be particularly vulnerable to mood effects from estradiol fluctuations, as suggested by the North American Menopause Society 3

Treatment should continue as long as benefits outweigh risks, according to the American College of Physicians 1
Tapering rather than abrupt discontinuation of estradiol patches may be preferable in sensitive individuals to avoid withdrawal effects, according to the Endocrine Society 3
Clinicians should screen for psychiatric history, particularly focus on history of depression, anxiety, or perimenopausal mood disorders, and monitor for mood changes during initiation and dose adjustments of estradiol patches, as advised by the American College of Obstetricians and Gynecologists 4

Transdermal estrogen administration may be preferred when mood symptoms are a primary concern, as suggested by the American Association of Clinical Endocrinologists 4 and the American College of Obstetricians and Gynecologists 5

Low estrogen levels can contribute to anxiety symptoms in susceptible individuals, with evidence showing that estrogen has anxiolytic effects through its actions on brain regions like the hippocampus and amygdala 4, 5
Cognitive behavioral therapy and pelvic floor exercises may help decrease anxiety in patients experiencing anxiety related to low estrogen, as suggested by the Journal of Clinical Oncology 2
Response to estrogen therapy varies based on genetic factors and prior psychiatric history, with genetic variations, including polymorphisms in the serotonin transporter gene (5-HTTLPR), catechol-O-methyltransferase (COMT), and monoamine oxidase-A (MAO-A), playing a significant role in determining individual sensitivity to hormone-related mood changes 6
Estrogen receptor polymorphisms may influence individual sensitivity to estrogen-related mood changes, although the specific details of this relationship are not fully understood 6
Stress and social support, such as family social support, can influence biological mechanisms and affect mood symptoms, with genetic vulnerability being expressed more strongly in the presence of stressful life events 6

For those with contraindications to hormone therapy, non-hormonal approaches should be considered 3
Hormone therapy, including estradiol patches, can cause psychiatric side effects in some individuals, particularly mood changes including depression and anxiety, with effects varying based on individual sensitivity to hormonal fluctuations 4
Withdrawal from estradiol can trigger depressive symptoms in vulnerable individuals, highlighting the importance of careful monitoring and tapering, as recommended by the American Psychiatric Association 4